Sona Nanotech Reports 80% Response Rate in First-In-Human THT Cancer Therapy Study
Halifax, Nova Scotia--(Newsfile Corp. - October 20, 2025) - Sona Nanotech Inc., (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), is pleased to announce the completion of its first-in-human clinical study treating patients with histologically confirmed, immunotherapy-resistant cutaneous metastatic melanoma using Sona's Targeted Hyperthermia Therapy ("THT"). Ten advanced-stage patients, all of whom were failing to respond to standard immunotherapy treatment, were recruited int
2025-10-20 6:00 AM EDT | Sona Nanotech Inc.
Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027
MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx™ in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA. New data from the ARCHER trial, highlighting the magnitude of reduction in left ventricular (LV) mass and the read through to heart failure, to be presented at a cardiology conference in November 2025. Next-generation therapy CR
Biotechnology, Cannabis, Health, Cannabis Manufacturer
2025-10-17 4:34 PM EDT | Cardiol Therapeutics Inc.
Sona Nanotech To Host Investor Webinar To Discuss Clinical Study
Halifax, Nova Scotia--(Newsfile Corp. - October 17, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), announces that it will host a webinar on Monday, October 20th at noon EDT to discuss its first-in-human, early feasibility clinical study for its Targeted Hyperthermia Therapy cancer treatment. Ten advanced stage melanoma patients who were failing to respond to standard immunotherapy treatment were recruited into this early feasibility stu
2025-10-17 4:04 PM EDT | Sona Nanotech Inc.
OS Therapies Granted Final Type C Meeting by U.S. FDA and pre-MAA Meeting by U.K. MHRA for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
New York, New York--(Newsfile Corp. - October 17, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug co
2025-10-17 9:15 AM EDT | OS Therapies
PharmaTher Applauds FDA's Commissioner's National Priority Voucher (CNPV) Selection of Ketamine; Company Highlights Potential Ketamine Opportunity, 505(b)(2) Focus, and Upside from Strategic ANDA Sale
Toronto, Ontario--(Newsfile Corp. - October 17, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking the pharmaceutical potential of ketamine, today applauds the U.S. Food and Drug Administration's ("FDA") announcement on October 16, 2025 of the first-ever recipients of the new Commissioner's National Priority Voucher ("CNPV") pilot program, which include "ketamine for domestic manufacturing of a
Biotechnology, Pharmaceuticals
2025-10-17 8:26 AM EDT | PharmaTher Holdings Ltd.
InMed Pharmaceuticals Appoints Mr. John Bathery to Its Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - October 16, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the appointment of Mr. John Bathery to its Board of Directors, effective immediately. Mr. Bathery brings more than 30 years of experience in the pharmaceutical industry, including over 15 yea
Biotechnology, Pharmaceuticals
2025-10-16 8:30 AM EDT | InMed Pharmaceuticals
PharmaTher Advances Phase 3 FDA Package for Ketamine in LID-Parkinson's Disease
Toronto, Ontario--(Newsfile Corp. - October 16, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking the pharmaceutical potential of ketamine, today announced that it has begun preparing its U.S. Food and Drug Administration ("FDA") briefing materials to discuss a Phase 3 program for ketamine in levodopa-induced dyskinesia in Parkinson's disease ("LID-PD") and that prospective pharma partn
Biotechnology, Pharmaceuticals
2025-10-16 8:00 AM EDT | PharmaTher Holdings Ltd.
Hemostemix Adds the Treatment of Refractory Angina to Its Phase 1 Basket Protocol
Calgary, Alberta--(Newsfile Corp. - October 15, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option individuals suffering from angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida under Florida's SB 1768, is pleased to annou
Biotechnology, Pharmaceuticals, Health
2025-10-15 3:51 PM EDT | Hemostemix Inc.
Marc Walther, President and CEO of Impact Fusion Files a Patent Pending Related to Artificial Insemination of Mammals
Napoleonville, Louisiana--(Newsfile Corp. - October 15, 2025) - Impact Fusion (OTCID: IFUS) announced today, that Marc Walther, President and CEO filed a Patent Pending on Thursday October 9, 2025 with the USPO related to the artificial insemination of mammals. Impact Fusion Artificial Insemination Technology™ (Impact Fusion AIT™) is available now. "I have long been aware of the importance of dairymen and cattle ranchers being able to have access to reliable, cos
2025-10-15 1:15 PM EDT | Impact Fusion International Inc.
PharmaTher Announces KetAImine(TM) - AI Discovery Platform to Expand the Ketamine Portfolio, Enable Earlier Partnering, and Fast-Track 505(b)(2) NDA Filings
Toronto, Ontario--(Newsfile Corp. - October 15, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking the pharmaceutical potential of ketamine, today announced KetAImine™, a proprietary ketamine repurposing and discovery platform designed to create, prioritize, and de-risk new ketamine indications and combination therapies across therapeutic areas—forming a scalable pipeline for
Biotechnology, Pharmaceuticals
2025-10-15 8:00 AM EDT | PharmaTher Holdings Ltd.
Kiora Pharmaceuticals to Participate in the 2025 Maxim Growth Summit and Eyecelerator @ AAO 2025
Encinitas, California--(Newsfile Corp. - October 15, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that it will participate in an ophthalmology panel at the upcoming 2025 Maxim Growth Summit in New York and give an overview of its development pipeline at Eyecelerator @ AAO 2025 in Orlando. Maxim Growth Summit Ophthalmology Panel Details Title: A vision of innovation; Advances in biotechnology have spurred innovation in the manageme
Biotechnology, Pharmaceuticals
2025-10-15 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
TempraMed to Commence Trading on the Canadian Securities Exchange Under Symbol "VIVI", Today, October 15, 2025
Vancouver, British Columbia--(Newsfile Corp. - October 15, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company") is pleased to announce that it has received approval to list its common shares (the "Common Shares") on the Canadian Securities Exchange ("CSE"). Trading is expected to commence on CSE under symbol "VIVI" at the open of markets on October 15, 2025. Further, the board of directors (the "Board") of the Compa
Technology, Biotechnology, Pharmaceuticals, Health
2025-10-15 7:00 AM EDT | TempraMed Technologies Ltd.
Sharp Therapeutics Arranges Non-Brokered Private Placement
Pennsylvania and Toronto, Ontario--(Newsfile Corp. - October 14, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company"), is pleased to announce that it is arranging a non-brokered private placement to raise gross proceeds of not less than US$10,000,000 (the "Offering"). The placement will consist of common shares in the capital of the Company priced at not less than US$2.50 per share. The Company expects the offering to close i
2025-10-14 11:22 AM EDT | Sharp Therapeutics Corp.
CBIH Announces Women-First Fertility Innovation Built on Nanoemulsion Delivery
Houston, Texas--(Newsfile Corp. - October 13, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) today announced the addition of a patent-pending nanoemulsion formulation to its growing portfolio, developed to support female fertility and reproductive function in women of advanced maternal age (35+). CBIH believes this innovation should expand evidence-based options for patients and partners. As age is a key determinant of reproductive outcomes—and first births
Biotechnology, Pharmaceuticals, Cannabis, Health
2025-10-13 7:00 AM EDT | Cannabis Bioscience International Holdings
PreveCeutical Announces Results from Annual General and Special Meeting and Increase to Size of Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - October 10, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that all resolutions presented at the Company's annual general and special meeting (the "Meeting") held on Friday, October 10, 2025, including the following: the election of Stephen Van Deventer, Makarand Jawadekar, Kathlee
Biotechnology, Pharmaceuticals, Health
2025-10-10 4:00 PM EDT | PreveCeutical Medical Inc.
TempraMed Receives Final Receipt for Prospectus and Closes Reverse Takeover Transaction of TempraMed Israel
Vancouver, British Columbia--(Newsfile Corp. - October 10, 2025) - TempraMed Technologies Ltd. (the "Company") is pleased to announce that the Company has filed and obtained a receipt on September 29, 2025, for its final long form prospectus dated September 25, 2025 (the "Prospectus"), with the British Columbia Securities Commission and is now a reporting issuer in the Province of British Columbia, effective as of September 29, 2025. The Prospectus was filed for, among other thi
Technology, Biotechnology, Pharmaceuticals, Health
2025-10-10 7:00 AM EDT | TempraMed Technologies Ltd.
Therma Bright Appoints US Healthcare Veteran Michael Raimondo to the Board of Directors
Toronto, Ontario--(Newsfile Corp. - October 10, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner in advanced diagnostic and medical device technologies, is pleased to announce the appointment of Michael Raimondo, a 30-year veteran in sales and operations in the healthcare industry to its Board of Directors. Michael was part of Therma's advisory Board, previously announced on August 13, 2024. Mr. Raimondo
Technology, Biotechnology, Health
2025-10-10 6:30 AM EDT | Therma Bright Inc.
OS Therapies Announces Statistically Significant Positive Final 2-Year Overall Survival Data from Phase 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully-Resected, Pulmonary Metastatic Osteosarcoma
New York, New York--(Newsfile Corp. - October 10, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conj
2025-10-10 6:00 AM EDT | OS Therapies
Envoy Medical Announces Closing of Up to $16 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
White Bear Lake, Minnesota--(Newsfile Corp. - October 9, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of 3,007,524 shares of its Class A common stock at a purchase price of $1.33 per share. In addition, in a concurrent private placement, Envoy Medical issued
Biotechnology, Healthcare and Hospitals
2025-10-09 4:05 PM EDT | Envoy Medical, Inc.
Global Hemp Group Applies for Partial Revocation Order and Announces Proposed Financing
Vancouver, British Columbia--(Newsfile Corp. - October 9, 2025) - Global Hemp Group Inc. (CSE: GHG) (OTC Pink: GBHPF) (FSE: GHG0) ("GHG" or the "Company") announces that it has applied to the British Columbia Securities Commission ("BCSC") for a partial revocation order (the "Partial Revocation Order") in connection with the failure-to-file cease trade order ("FFCTO") issued against the Company on April 15, 2025, for failing to file certain continu
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Cannabis
2025-10-09 9:29 AM EDT | Global Hemp Group Inc.